


The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) ~~Testosterone derivatives of general~~ A testosterone compound of formula I



in which

R<sup>6</sup> represents is a hydrogen atom, a hydroxy group, a C<sub>1</sub>-C<sub>10</sub> alkoxy group, a C<sub>1</sub>-C<sub>10</sub> alkanoyloxy group or a halogen atom,

R<sup>15</sup> and R<sup>16</sup> each are a hydrogen atom or together form a bond,

R<sup>17a</sup> represents is a C<sub>1</sub>-C<sub>4</sub> alkyl group, a C<sub>2</sub>-C<sub>4</sub> alkinyl group, or a radical of formula Formula C<sub>n</sub>F<sub>m</sub>H<sub>o</sub>, whereby wherein n = 1, 2, 3 or 4, m > 1 and m+o=2n+1,

R<sup>17b</sup> is a hydroxy group, a C<sub>1</sub>-C<sub>10</sub> alkoxy group or a C<sub>1</sub>-C<sub>10</sub> alkanoyloxy group,

A is an unbranched C<sub>6</sub>-C<sub>13</sub> alkylene group,

B represents is an oxygen atom, a grouping -S(O)<sub>p</sub> group, whereby wherein p = 0, 1 or 2, an iminocarbonyl group -C(O)N(Y)-, an imino group -N(Y)-, a carbonylimino group -N(Y)C(O)-, a sulfonylimino group -N(Y)S(O)<sub>2</sub>-, whereby wherein Y is a hydrogen atom or a C<sub>1</sub>-C<sub>8</sub> alkyl group, a sulfonyloxy group -OS(O)<sub>2</sub>-, a dimethylsilyloxy group -O-Si(CH<sub>3</sub>)<sub>2</sub>- or a carbonylsulfanyl group -SC(O)-, or B represents is a bond between A and C, or together with C forms a bond between A and D,

C ~~represents~~ is a bond between B and D, or together with B forms a bond between A and D, or an unbranched C<sub>1</sub>-C<sub>6</sub> alkylene group, a phenylene group, a substituted phenylene group, a five-ring or six-ring heteroarylene group, a substituted five-ring or six-ring heteroarylene group, or a five-ring or six-ring heteroarylene group that is condensed with a phenyl ring,

and

D ~~represents~~ is a hydrogen atom, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a vinyl group, a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl group, a bis(C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl)methyl group, an acetyl(C<sub>1</sub>-C<sub>4</sub> alkoxycarbonyl)methyl group, a cyano group, a carboxy group, an azide group, a hydroxy group, a halogen atom or a radical of formula C<sub>n</sub>F<sub>m</sub>H<sub>o</sub>, ~~whereby~~ wherein n = 1, 2, 3 or 4, m > 1 and m+o=2n+1.

2. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, ~~characterized in that~~ wherein R<sup>17a</sup> ~~represents the~~ is a methyl group, ~~the~~ an ethyl group, ~~the~~ a trifluoromethyl group or ~~the~~ a pentafluoroethyl group.

3. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R<sup>17b</sup> is ~~the~~ a hydroxy group, a C<sub>1</sub>-C<sub>5</sub> alkoxy group or a C<sub>1</sub>-C<sub>3</sub> alkanoyloxy group.

4. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 3, wherein R<sup>17b</sup> is ~~the~~ a hydroxy, methoxy, ethoxy or acetoxy group.

5. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R<sup>6</sup> ~~represents~~ is a hydrogen atom, ~~the~~ a hydroxy group or a halogen atom.

6. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R<sup>15</sup> and R<sup>16</sup> each represent a hydrogen atom.

7. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to

claim 1, wherein radical ABCD means is 9-hydroxynonyl, 7-(acetylsulfanyl)heptyl or 7-(4-cyanobutoxy)heptyl.

8. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein the five-ring- or six-ring-heteroaromatic ~~compound~~ compounds of radical C are is pyrrole, thiophene, imidazole, thiazole, oxazole, triazole, thiadiazole, indole, benzoxazole, benzothiazole, pyridine, or pyrimidine.

9. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, ~~wherein they represent the following compounds:~~ that is

*C  
C  
C*

7 $\alpha$ -(9-Chlorononyl)-17 $\alpha$ -methyl-3-oxoandrost-4-en-17 $\beta$ -yl-acetate,  
7 $\alpha$ -(9-Chlorononyl)-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-7 $\alpha$ -(9-iodononyl)-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-7 $\alpha$ -(9-hydroxynonyl)-17 $\alpha$ -methylandrost-4-en-3-one,  
7 $\alpha$ -(10-Chlorodecyl)-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-7 $\alpha$ -(11-hydroxyundecyl)-17 $\alpha$ -methylandrost-4-en-3-one,  
7 $\alpha$ -(11-Bromoundecyl)-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-7 $\alpha$ -[7-(phenylsulfanyl)heptyl]androst-4-en-3-one,  
17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]nonyl]androst-4-en-3-one,  
17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-7 $\alpha$ -[9-(phenylsulfanyl)nonyl]androst-4-en-3-one,  
7 $\alpha$ -[9-[(5-Chloropentyl)sulfanyl]nonyl]-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-7 $\alpha$ -[9-[(5-hydroxypentyl)sulfanyl]nonyl]-17 $\alpha$ -methylandrost-4-en-3-one,  
7 $\alpha$ -(9-Azidononyl)-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
7 $\alpha$ -[7-(Acetylsulfanyl)heptyl]-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one,  
17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-7 $\alpha$ -[7-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]heptyl]androst-4-en-3-one,  
N-[7-(17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-7 $\alpha$ -yl)heptyl]pentanamide,  
17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-7 $\alpha$ -octane nitrile,  
5-[[7-(17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-7 $\alpha$ -yl)heptyl]oxy]pentanenitrile,

17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]androst-4-en-3-one,  
or

N-[9-(17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-7 $\alpha$ -yl)nonyl]methanesulfonamide, or  
7 $\alpha$ -(9-Chlorononyl)-6 $\beta$ -hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-17 $\beta$ -yl-acetate.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

*C  
Cancelled*  
13. (Currently Amended) Pharmaceutical agents A pharmaceutical composition that  
contain comprising at least one testosterone derivative of general compound of formula I  
according to claim 1 and one or more physiologically compatible acceptable adjuvants and/or  
vehicles that are commonly used in galenicals.

14. (New) A method for the long-term antiandrogen therapy of an androgen-dependent disease comprising administering to a patient in need thereof a pharmaceutical composition in accord with claim 13.

15. (New) A method according to claim 14, wherein the androgen-dependent disease is prostate cancer.

16. (New) A method for the long-term antiandrogen therapy of prostate cancer comprising administering to a patient in need thereof a pharmaceutical composition comprising at least one testosterone compound of formula I according to claim 9 and one or more physiologically acceptable adjuvants and/or vehicles.

17. (New) A method for the long-term antiandrogen therapy of prostate cancer comprising administering to a patient in need thereof a pharmaceutical composition comprising

17 $\beta$ -Hydroxy-7 $\alpha$ -(9-hydroxynonyl)-17 $\alpha$ -methylandrost-4-en-3-one, 7 $\alpha$ -[7-(Acetylsulfanyl)heptyl]-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-en-3-one, or 5-[[7-(17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoandrost-4-en-7 $\alpha$ -yl)heptyl]oxy]pentanenitrile according to claim 9 and one or more physiologically acceptable adjuvants and/or vehicles.